Crispr therapeutics CEO Samarth Kulkarni sells shares worth 1.67 million
| SCHLX Fund | USD 42.62 0.27 0.63% |
Slightly above 62% of Deutsche Health's investor base is looking to short. The analysis of overall sentiment of trading Deutsche Health And mutual fund suggests that many investors are alarmed at this time. Deutsche Health's investing sentiment can be driven by a variety of factors including economic data, Deutsche Health's earnings reports, geopolitical events, and overall market trends.
Deutsche |
Crispr therapeutics CEO Samarth Kulkarni sells shares worth 1.67 million
Read at investing.com
 |
Deutsche Health Fundamental Analysis
We analyze Deutsche Health's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Deutsche Health using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Deutsche Health based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Deutsche Health And Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Deutsche Health mutual fund to make a market-neutral strategy. Peer analysis of Deutsche Health could also be used in its relative valuation, which is a method of valuing Deutsche Health by comparing valuation metrics with similar companies.
Peers
Deutsche Health Related Equities
| BIGLX | Blackrock | 0.11 | ||||
| SMAAX | Aig Government | 0.1 | ||||
| SSAGX | Virtus Seix | 0.00 | ||||
| LCCXX | Lord Abbett | 0.00 | ||||
| VSBSX | Vanguard Short-term | 0.05 | ||||
| JGIFX | John Hancock | 0.13 | ||||
| AGIVX | Invesco Us | 0.14 |
Other Information on Investing in Deutsche Mutual Fund
Deutsche Health financial ratios help investors to determine whether Deutsche Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Deutsche with respect to the benefits of owning Deutsche Health security.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |